Figure 1.
Trial schema—two doses of ipilimumab were given prior to tumor-infiltrating lymphocyte (TIL) infusion and two doses were given after cell infusion. One of the pre-infusion doses was given 2 weeks prior to the TIL harvest. Imaging time points included computed tomography chest, abdomen, and pelvis with MRI brain. Peripheral blood drawn at indicated time points was used for correlative studies.